Long lasting response to second-line everolimus in kidney cancer

查看全文 作　　者：Antonella [1]Virtuoso;Tania [1]Policastro;Michela [1]Izzo;Piera [1]Federico;Carlo [1]Buonerba;Pasquale [1]Rescigno;Giuseppe Di [1,2]Lorenzo

机构地区：[1]Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico Ⅱ,80131 Naples,Italy;[2]Deparment of Clinical Medicine, University Federico Ⅱ of Naples,80131 Naples, Italy

出　　处：《World Journal of Clinical Cases》索引2013年第1卷第5期,共3页

摘　　要：In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival(PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus. 关键词：METASTATIC RENAL cell carcinoma Everolimus(RAD001) SUNITINIB Progression-free survival

相关文献

参考文献（7）
引证文献（6）
耦合文献（0）

参考文献(7)

引证文献(6)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Long lasting response to second-line everolimus in kidney cancer

参考文献(7)

引证文献(6)

用户提示